<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257776</url>
  </required_header>
  <id_info>
    <org_study_id>CeTMAd/ICPD/2008</org_study_id>
    <nct_id>NCT01257776</nct_id>
    <nct_alias>NCT01079403</nct_alias>
  </id_info>
  <brief_title>Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients</brief_title>
  <official_title>Using Mesenchymal Stem Cells From Adipose Tissue (CeTMAd) as Cell Regeneration Therapy in Chronic Ischemic Syndrome of Lower Limbs in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, open, randomized, parallel-group controlled study for two levels
      of dose.

      The study population will consist of 30 non-diabetic patients with critical chronic ischemia
      in at least one of the lower limbs (CLI) and without possibility of revascularization, from
      whom results can clinically be evaluable, of whom, 20 patients will be included in the
      experimental group (10 for each dose level) and 10 in the control group.

      In each of the two dose levels to be used in the study, 15 patients will be included, who
      will be randomized to the experimental group or the control group according to a distribution
      2:1 (2 patients in the experimental group and 1 in control group), thus at each dose level,
      we will have 10 patients in the experimental group (treated with mesenchymal cells of adipose
      tissue) and 5 patients in the control group (conventional treatment)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic assessment of neovasculogenesis (angiogenesis plus arteriogenesis)</measure>
    <time_frame>6 months</time_frame>
    <description>Target limb vascularization would be quantified by a dedicated software, MetaMorph® v.6.3, by using Angiogenesis Tube Formation application module. Neovasculogenesis would be the difference between vascularization at baseline and 6 months follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse event (death, target limb amputation)</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ankle Brachial Index</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of Texas Classification at target limb</measure>
    <time_frame>1 month, 6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Critical Limb Ischemia (CLI)</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells 0,5 million * weight (kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of low dose of Mesenchymal stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells 1 million * weight (kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of mid dose of mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Controlled group with no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous adipose derived mesenchymal stem cells</intervention_name>
    <description>Intra-arterial administration through a selective cannulation of target common femoral artery</description>
    <arm_group_label>Mesenchymal stem cells 0,5 million * weight (kg)</arm_group_label>
    <arm_group_label>Mesenchymal stem cells 1 million * weight (kg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes, type 1 or 2

          -  Critical Limb Ischemia (Rutherford Becker Class II,III or IV)of at least one limb.

          -  No options for target limb revascularization.

        Exclusion Criteria:

          -  Cancer antecedent in the last two years

          -  Current limb infection or limb gangrene
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael J Ruiz-Salmeron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen Macarena. Seville.Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio De la Cuesta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Virgen Macarena. Seville.Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine)</name>
      <address>
        <city>Seville</city>
        <zip>41092</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Limb Ischemia (CLI)</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Regenerative Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

